Related Experiment Video
Updated: Apr 18, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.9K
The long-term outcomes of systemic vasculitis
Kerstin Westman1, Oliver Flossmann2, Gina Gregorini3
1Department of Nephrology, Clinical Sciences, Lund University, Skane University Hospital Malmö, Lund, Sweden.
Summary
Long-term outcomes for ANCA-associated vasculitis (AAV) patients are crucial. This review examines relapse rates, survival, and adverse events in AAV patients from EUVAS trials, focusing on improving long-term patient care.
Area of Science:
- Rheumatology and Immunology
- Clinical Trials and Outcomes Research
Background:
- Generalized ANCA-associated small vessel vasculitis (AAV) historically has a poor prognosis without timely diagnosis and treatment.
- Immunosuppressive therapy has improved survival but carries significant side effects and a high relapse rate (nearly 50%).
- Previous outcome reports for AAV patients are often heterogeneous in diagnosis, treatment, and follow-up.
Purpose of the Study:
- To evaluate the long-term effects and adverse events of original randomized trials conducted by the European Vasculitis Society (EUVAS).
- To provide a comprehensive overview of long-term outcomes in ANCA-associated vasculitis patients.
- To focus on critical long-term endpoints including relapse rate, patient and renal survival, and the incidence of cardiovascular disease and malignancy.
Main Methods:
- Analysis of long-term follow-up data from patients with newly diagnosed AAV participating in independent EUVAS clinical trials since 1995.
- Stratification of patient groups based on renal function and disease localization (generalized vs. localized forms).
- Review of original randomized trials to assess treatment efficacy and potential adverse events over extended periods.
Main Results:
- While immediate survival has improved with immunosuppressive therapy, long-term outcomes, including relapse rates and adverse events, require further detailed evaluation.
- The heterogeneity of previous AAV patient cohorts necessitates a focused review of standardized trial data.
- Focus on long-term endpoints such as patient survival, renal survival, cardiovascular disease, and malignancy is essential for comprehensive AAV management.
Conclusions:
- Long-term follow-up is critical for understanding the full impact of AAV and its treatments.
- EUVAS trials provide a valuable, standardized dataset for evaluating long-term outcomes in AAV.
- Further analysis of these trials will inform strategies to mitigate long-term risks like relapse, cardiovascular events, and malignancy in AAV patients.
Related Concept Videos
01:29Acute Kidney Injury III: Clinical Manifestations
1.6K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.6K
01:26Nephrotic Syndrome II : Assessment and Medical Management
378
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
378
01:18Endocarditis III: Medical Management
351
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
351
01:25Endocarditis II: Clinical Features of Infective Endocarditis
898
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
898
01:12Chronic Inflammation: Introduction
4
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
4
01:23Rheumatic Heart Disease I: Introduction
991
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
991